Kidney Cancer Update The year in review in kidney cancer.

Kidney Cancer Update The year in review in kidney cancer. Clin Adv Hematol Oncol. 2015 May;13(5):327-9 Authors: PMID: 26352778 [PubMed - in process]
Source: Clinical Advances in Hematology and Oncology - Category: Cancer & Oncology Tags: Clin Adv Hematol Oncol Source Type: research

Related Links:

This study aimed to investigate mRNA expression of SPINK13 in clear cell renal cell carcinoma (CCRCC) in human tissue and to use bioinformatics data to investigate the role of SPINK13 expression as a clinicopathological and prognostic biomarker for patients with CCRCC. MATERIAL AND METHODS Patients with CCRCC (N=533) with available RNA sequence data from The Cancer Genome Atlas (TCGA)-CCRCC database were analyzed with patients who had a tissue diagnosis of CCRCC (N=305) at the Fudan University Shanghai Cancer Center (FUSCC). Differential transcriptional and proteome expression profiles were obtained from the ONCOMINE cance...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
ConclusionThe above results indicate that 6-gingerol can induce cell-cycle arrest and cell-growth inhibition through the AKT –GSK 3β–cyclin D1 signaling pathway in vitro and in vivo, suggesting that 6-gingerol should be useful for renal-cell carcinoma treatment.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
(Emory Health Sciences) Patients with well-supported immune cells in their tumors are more likely to control their cancers' growth for a longer time, an observation that could guide treatment decisions after surgery for kidney cancer. In addition, the findings could help researchers expand the dramatic but sparse benefits of cancer immunotherapy to more people.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
This report outlines a translational PK-pharmacodynamic (PD) methodology used to derive a baseline composite cytokine signature correlated with nivolumab clearance using data from three clinical trials in which nivolumab or everolimus was administered.MethodsPeripheral serum cytokine (PD) and nivolumab clearance (PK) data from patients with RCC were analyzed using a PK-PD machine-learning model. Nivolumab studies CheckMate 009 (NCT01358721) and CheckMate 025 (NCT01668784) (n = 480) were used for PK-PD analysis model development and cytokine feature selection (training dataset). Validation of the model and asses...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
In the last decades, the prognosis of metastatic renal cell carcinoma (mRCC) has remarkably improved following the advent of the “targeted therapy” era. The expanding knowledge on the prominent role played by angiogenesis in RCC pathogenesis has led to approval of multiple anti-angiogenic agents such as sunitinib, pazopanib, axitinib, cabozantinib, sorafenib, and bevacizumab. These agents can induce radiological responses and delay cancer progression for months or years before onset of resistance, with a clinically meaningful activity. The need for markers of prognosis and efficacy of anti-angiogenic agents has...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 10 December 2019Source: Seminars in Ultrasound, CT and MRIAuthor(s): Satheesh Krishna, Ashley Leckie, Ania Kielar, Robert Hartman, Ashish KhandelwalAbstractCystic renal masses are common incidental findings on cross-sectional imaging. Accurate characterisation of cystic renal masses is essential to guide management. Renal mass protocol comprises of a good quality non-contrast, corticomedullary and nephrographic phases with each phase providing complementary information for diagnosis. Attenuation measurements in different phases are central to the ‘golden-rules’ in renal mass i...
Source: Seminars in Ultrasound, CT and MRI - Category: Radiology Source Type: research
In this study, the gene expression profiles and clinical data of ccRCC patients were downloaded from The Cancer Genome Atlas database and the cBioPortal database, respectively. IRGs were obtained from the ImmPort database. We analyzed the expression of IRGs in ccRCC, and discovered 681 that were differentially expressed between ccRCC and normal kidney tissues. Univariate Cox regression analysis was used to identify prognostic differentially expressed IRGs (PDEIRGs). Using Lasso regression and multivariate Cox regression analyses, we detected seven optimal PDEIRGs (PLAU, ISG15, IRF9, ARG2, RNASE2, SEMA3G and UCN) and used t...
Source: Aging - Category: Biomedical Science Authors: Tags: Aging (Albany NY) Source Type: research
AbstractPurposeTo identify the optimum response criteria for first-line targeted pazopanib therapy in patients with mRCC using solid tumor response criteria and clinical risk factors.MethodsPre- and post-treatment CTs of patients (n = 43) with mRCC treated with first-line pazopanib therapy were analyzed retrospectively. Treatment response was evaluated with Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Choi, modified Choi (mChoi), revised Choi (rChoi), MASS (Morphology, Attenuation, Size, and Structure), 10% threshold criteria, and subjective assessment. Memorial Sloan-Kettering Cancer Center an...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Treatment with chimeric antigen receptor-modified T cell (CAR-T) has demonstrated promising therapeutic efficacy in hematologic malignancies. However, the therapeutic efficacy is still very limited for solid tumors. An immunosuppressive microenvironment is one of the main reasons for the limited efficacy. Some chemotherapeutic agents exhibit immune microenvironment modulation. Therefore, combination with chemotherapeutic agents may be one of the promising strategies to enhance the therapeutic efficacy of CAR-T against solid tumors. Sunitinib modulates the antitumor immune response by improving T-cell infiltration and funct...
Source: Journal of Immunotherapy - Category: Allergy & Immunology Tags: Basic Study Source Type: research
In this study, we comprehensively surveyed the specifically expressed genes (SEGs) using the SEGtool based on the big data of gene expression from the The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) projects. In 15 solid tumors, we identified 233 cancer-specific SEGs (cSEGs), which were specifically expressed in only one cancer and showed great potential to be diagnostic biomarkers. Among them, three cSEGs (OGDH, MUDENG and ACO2) had a sample frequency>80% in kidney cancer, suggesting their high sensitivity. Furthermore, we identified 254 cSEGs as early-stage diagnostic biomarkers across 17 canc...
Source: Briefings in Bioinformatics - Category: Bioinformatics Authors: Tags: Brief Bioinform Source Type: research
More News: Cancer | Cancer & Oncology | Hematology | Kidney Cancer | Urology & Nephrology